Trials / Completed
CompletedNCT01735786
EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)
EndoClotTM Absorbable Polysaccharide Hemostat for Preventing Rbleeding After Endoscopic Mucosal Resection (EMR)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 164 (actual)
- Sponsor
- Xijing Hospital of Digestive Diseases · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment techniques of gastrointestinal small lesions. Postoperative rebleeding is one of the common complication following EMR. Several endoscopic hemostasis methods are currently in use. EndoClot® absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic application remains unknown. This study has been designed to observe the effect of rebleeding prevention after EMR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | EndoClot | EndoClot hemostat is applied immediately after EMR to achieve hemostasis. |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-02-01
- Completion
- 2012-03-01
- First posted
- 2012-11-28
- Last updated
- 2012-11-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01735786. Inclusion in this directory is not an endorsement.